| Literature DB >> 28210507 |
Toan Pham1, Bob Anh Tran2, Kevin Ooi1, Marcus Mykytowycz2, Stephen McLaughlin1, Matthew Croxford1, Iain Skinner1, Ian Faragher1.
Abstract
Introduction. We aimed to assess the efficacy and safety of digital subtraction angiography (DSA) and super-selective mesenteric artery embolization (SMAE) in managing lower GI bleeding (LGIB). Method. A retrospective case series of patients with LGIB treated with SMAE in our health service. Patients with confirmed active LGIB, on either radionuclide scintigraphy (RS) or contrast-enhanced multidetector CT angiography (CE-MDCT), were referred for DSA +/- SMAE. Data collected included patient characteristics, screening modality, bleeding territory, embolization technique, technical and clinical success, short-term to medium-term complications, 30-day mortality, and progression to surgery related to procedural failure or complications. Results. There were fifty-five hospital admissions with acute unstable lower gastrointestinal bleeding which were demonstrable on CE-MDCT or RS over a 31-month period. Eighteen patients proceed to embolization, with immediate success in all. Eight patients (44%) had clinical rebleeding after intervention, warranting repeated imaging. Only one case (5.6%) demonstrated radiological rebleeding and was reembolized. Complication rate was excellent: no bowel ischaemia, ischaemic stricture, progression to surgery, or 30-day mortality. Conclusion. SMAE is a viable, safe, and effective first-line management for localised LGIB. Our results overall compare favourably with the published experiences of other institutions. It is now accepted practice at our institution to manage localised LGIB with embolization.Entities:
Year: 2017 PMID: 28210507 PMCID: PMC5292126 DOI: 10.1155/2017/1074804
Source DB: PubMed Journal: Radiol Res Pract ISSN: 2090-195X
Demography.
| Demography | Number |
|---|---|
| Gender | |
| (i) Male | 12 (67%) |
| (ii) Female | 6 (33%) |
| Median age | 74.50 (range: 59–92) |
| Comorbidities | |
| (i) Ischaemic heart disease | 7 (39%) |
| (ii) Atrial fibrillation | 3 (17%) |
| (iii) Hypertension | 12 (67%) |
| (iv) Diabetes | 6 (33%) |
| Anticoagulation | |
| (i) Aspirin | 6 (33%) |
| (ii) Aspirin + clopidogrel | 3 (17%) |
| (iii) Warfarin | 1 (6%) |
Figure 1Presumptive aetiology of LGIB.
Figure 2Diagnostic imaging modality performed.
Figure 3Location of bleeding sites by vascular territory.
Figure 4Super-selective embolization: (a) before and (b) after coil deployment.
Comparisons of outcomes with other series.
| Outcomes | Current study | Rider et al. [ | Tan et al. [ | Waugh et al. [ |
|---|---|---|---|---|
| Immediate hemostasis | 100% | 100% | 97% | 96% |
| Rebleeding | 19% | 4.3% | 63% | 29.6% |
| Repeated embolization | 6% | 4.3% | 3% | 22% |
| Ischaemia | 0% | 8.7% | 3% | 15% |
| Progression to surgery | 0% | 12.5% | 28% (4 rebleeding; 1 incomplete hemostasis; 1 ischemia; 3 surgeon decision) | 7.4% |
| 30 d mortality | 0% | 0% | 9% | 7.4% |
| Ischaemic stricture | 0% | 4.3% | Not reported | Not reported |